Survivorship Program Increases Satisfaction, Improves Quality of Life in Recurrent Breast Cancer

October 2nd 2019, 1:00am


“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

Addition of CDK4/6 Inhibitors to Faslodex Improves Survival in Breast Cancer Subgroup

September 30th 2019, 5:49pm


Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

Frontline Tagrisso Improves Survival Among Specific Subgroup of Patients with NSCLC

September 30th 2019, 12:00am


First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

Opdivo-Yervoy Combination Induces Long-Term Survival in Metastatic Melanoma

September 29th 2019, 10:00pm


One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

Frontline Zejula Maintenance Therapy Improves Survival in Advanced Ovarian Cancer

September 29th 2019, 6:00pm


Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

Frontline Opdivo, Yervoy May Improve Survival in Non-Small Cell Lung Cancer

September 29th 2019, 1:00am


First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

Addition of PARP Inhibitor to Maintenance Therapy May Improve Survival in Ovarian Cancer

September 28th 2019, 11:18pm


The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

Erleada May Extend Subsequent Progression in Men With Castration-Resistant Prostate Cancer

September 28th 2019, 6:43pm


Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.